Contraline Announces Acceptance of Abstracts to be Presented at 2023 American Urology Association and European Association of Urology Annual Meetings

CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–#birthcontrol–Contraline, Inc., a clinical-stage medical device company announced the acceptance of abstracts detailing the initial results from the company’s first in human clinical trial of ADAM, a hydrogel-based, long-lasting, non-hormonal, and non-permanent male contraceptive. The abstracts were written and submitted by investigators leading the study, and were accepted for presentation at the two … [Read more…]

Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting

SAN DIEGO–(BUSINESS WIRE)–#ASCO23—Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that a poster describing initial data from the Phase 1/2 trial of AB-101 will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June … [Read more…]

BioAge Labs to Present on Therapeutics for Brain Aging Targeting NLRP3, Apelin, and Other Novel Pathways at Upcoming International Conferences

Company leadership and scientists will appear at LSX World Congress (May 3), Keystone conference on neurodegeneration (May 15–19), Age-related Disease Therapeutics Summit (June 1-2), and BIO International (June 7) RICHMOND, Calif.–(BUSINESS WIRE)–#aging–BioAge Labs, Inc. (“BioAge”), a privately held clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, … [Read more…]

American Vascular Associates Announces Growth Recapitalization by Petra Capital and Canopy Capital

TAMPA BAY, Fla.–(BUSINESS WIRE)–Officials with American Vascular Associates, LLC (AVA), a nationally recognized network of outpatient vascular and endovascular centers based in Palm Harbor, Fla., announced today the company’s completion of a growth recapitalization by two leading investment firms, Petra Capital Partners (Nashville, Tenn.) and Canopy Capital Partners (Tampa, Fla.). This transaction will allow for … [Read more…]

RGP Study Reveals the Systemic Impact of Healthcare Staffing Shortages on Mission-Critical Projects

IRVINE, Calif.–(BUSINESS WIRE)–#DareToWorkDifferently—RGP (Nasdaq: RGP), a global consulting firm, today released a new report that shows a significant number of healthcare service providers are failing at their mission-critical projects. The findings illustrate the impact of the industry’s growing clinical staffing shortages on all areas of the healthcare ecosystem. One in four healthcare executives report that … [Read more…]

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

PASADENA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer. Dr. Valente has more than 20 years of experience in late-stage biopharmaceutical product development, and she most recently … [Read more…]

XLerateHealth Partners with ScholarRx to Launch Suite of Entrepreneurship Education Products and Tools

Funded by the National Institutes of Health’s I-RED Award UT2GM148083 LOUISVILLE, Ky.–(BUSINESS WIRE)–XLerateHealth (XLH) is partnering with ScholarRx, a medical education technology company, to launch a suite of experience-based entrepreneurship education products and tools as part of a recent National Institutes of Health STTR $2.98 Million Phase II IDeA Regional Entrepreneurship Development (I-RED) Award. The … [Read more…]

Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

–Approximately 7.5 Million People in The U.S. Are Living with Generalized Anxiety Disorder (GAD) 1,2– MARLBOROUGH, Mass. & PRINCETON, N.J.–(BUSINESS WIRE)–#Sunovion—Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) … [Read more…]

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Preliminary Evidence of Durable Anatomical and Functional Improvements Following Administration of OpRegen Cells Extensive OpRegen Surgical Bleb Coverage of Areas of GA May Be Critical for Optimizing Patient Outcomes OCT Imaging With Segmentation Analysis is Advantageous in Assessment of Retinal Integrity Post-Treatment CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #LineageCellTherapeutics—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a … [Read more…]

Comfort Keepers® Certified as a Great Place to Work®; Company Provides Meaningful, Rewarding and Purposeful Career Opportunities for Today’s Caregiver

87% of Employees at Comfort Keepers Believe It’s a Great Place to Work Compared to 57% of Employees at a Typical U.S.-Based Company1 IRVINE, Calif.–(BUSINESS WIRE)–Comfort Keepers®, a market-leading provider of uplifting home care for seniors and adults who need assistance, has been awarded the Great Places to Work® Certification – a program managed by … [Read more…]